Mixed effect modeling of sumatriptan pharmacokinetics during drug development. I: Interspecies allometric scaling

• Published in: Journal of pharmacokinetics and biopharmaceutics 1997-04, Vol.25 (2), p.149-167
• Main Authors: COSSON, V. F, FUSEAU, E, EFTHYMIOPOULOS, C, BYE, A
• Format: Article
• Language: English
• Subjects: Animals; Biological and medical sciences; Biological Availability; Cardiovascular system; Dogs; Dose-Response Relationship, Drug; Drug Design; Female; General pharmacology; Humans; Male; Medical sciences; Models, Biological; Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions; Pharmacology. Drug treatments; Pregnancy; Rabbits; Rats; Reproducibility of Results; Serotonin Receptor Agonists - pharmacokinetics; Species Specificity; Studies; Sumatriptan - pharmacokinetics; Vasodilator agents. Cerebral vasodilators
• ISSN: 0090-466X; 1567-567X; 2168-5789; 1573-8744
• DOI: 10.1023/A:1025728028890

Allometric scaling is an empirical examination of the relationships between the pharmacokinetic parameters and size (usually body weight), but it can also involve brain weight for metabolized drug. Through all species, the protein binding of sumatriptan is similar (14-16%), and its metabolic pathway undergoes extensive oxidative deamination involving the monoamine oxidase A isoenzyme. These similarities across species suggested the possible relevance of an allometric analysis. Toxicokinetic data were collected from rats, pregnant rabbits, and dogs in animal pharmacokinetic studies where sumatriptan was administered intravenously to the animals at doses of 5 mg/kg. 0.25 mg/kg, and 1 mg/kg, respectively. Animal data were pooled and analyzed in one step using a mixed effect modeling (population) approach. The kinetic parameters predicted in any species were close to the observed values by species: 77 L/hr vs. 80 L/hr in man for total clearance, 137 L vs. 119 L for distribution volume at steady state. The value of the mixed effect modeling approach compared to the two-step method was demonstrated especially with the possibility of including covariates to describe the status of animal (e.g., pregnancy) in the model. Knowledge of the animal kinetics, dynamics, and metabolism of a drug contributes to optimal and expeditious development. Valuable information for the design of the first-dose-in-man study may emerge from more creative data analysis based on all the information collected during the preclinical and ongoing nonclinical evaluation of a new drug.